Enterprise Value

135.9B

Cash

12.74B

Avg Qtr Burn

N/A

Short % of Float

0.00%

Insider Ownership

0.01%

Institutional Own.

10.52%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Approved

Quarterly sales

Nirsevimab Details
Respiratory syncytial virus

PDUFA

Approval decision

Sarclisa® Details
Cancer, Multiple myeloma

Phase 3

Data readout

PRV-031 (Teplizumab) Details
Type 1 diabetes, Diabetes

Phase 3

Data readout

Frexalimab Details
Autoimmune disease, Multiple sclerosis

Phase 3

Initiation

Ordesekimab (PRV-015) (anti-IL-15) Details
Celiac disease, Immune Disorders

Big Mover™

Susp. Mover™

Phase 2b

Data readout

PRV-3279 Details
Systemic lupus erythematosus, Autoimmune disease

Phase 2a

Data readout